Sandbox/AL: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
No edit summary
Line 1: Line 1:
__NOTOC__
__NOTOC__
 
{{Sildenafil}}
{{Rivaroxaban}}
{{CMG}}; {{AE}} {{PB}}
 
'''''For patient information, click [[Sildenafil (patient information)|here]]'''''.
{{CMG}}; {{AE}} {{AZ}}
 
'''''For patient information, click <u>[[Rivaroxaban (patient information)|here]]'''''</u>.
{{SB}} XARELTO<sup>®</sup>


==Overview==
==Overview==
'''Rivaroxaban''' (BAY 59-7939) is an [[route of administration|oral]] [[anticoagulant]]  invented and manufactured by [[Bayer]]; in a number of countries it is marketed as '''Xarelto'''.<ref name="Xarelto SPC">{{cite web |url=http://www.xarelto.com/scripts/pages/en/information-on-xarelto/summary_of_product_characteristics/index.php |title=Xarelto: Summary of Product Characteristics |publisher=Bayer Schering Pharma AG |year=2008 |accessdate=2009-02-11}}</ref> In the United States, it is marketed by [[Janssen Pharmaceutica]].<ref name="US Approval">{{cite press release |title=FDA Approves XARELTO® (rivaroxaban tablets) to Help Prevent Deep Vein Thrombosis in Patients Undergoing Knee or Hip Replacement Surgery |publisher=[[Janssen Pharmaceutica]] |date=2011-07-01 |url=http://m.prnewswire.com/news-releases/fda-approves-xarelto-rivaroxaban-tablets-to-help-prevent-deep-vein-thrombosis-in-patients-undergoing-knee-or-hip-replacement-surgery-124872829.html |accessdate=2011-07-01}}</ref> It is an orally active [[direct factor Xa inhibitor]]. Rivaroxaban is well absorbed from the gut and maximum inhibition of factor Xa occurs four hours after a dose. The effects lasts 8 to 12 hours, but factor Xa activity does not return to normal within 24 hours so once-daily dosing is possible.


==Category==
==Category==
Direct [[Xa factor]] inhibitor.
 
==US Brand Names==


==FDA Package Insert==
==FDA Package Insert==
=== XARELTO®===
'''| [[Rivaroxaban indications and usage|Indications and Usage]]'''
'''| [[Rivaroxaban dosage and administration|Dosage and Administration]]'''
'''| [[Rivaroxaban dosage forms and strengths|Dosage Forms and Strengths]]'''
'''| [[Rivaroxaban contraindications|Contraindications]]'''
'''| [[Rivaroxaban warnings and precautions|Warnings and Precautions]]'''
'''| [[Rivaroxaban adverse reactions|Adverse Reactions]]'''
'''| [[Rivaroxaban drug interactions|Drug Interactions]]'''
'''| [[Rivaroxaban use in specific populations|Use in Specific Populations]]'''
'''| [[Rivaroxaban overdosage|Overdosage]]'''
'''| [[Rivaroxaban description|Description]]'''
'''| [[Rivaroxaban clinical pharmacology|Clinical Pharmacology]]'''
'''| [[Rivaroxaban nonclinical toxicology|Nonclinical Toxicology]]'''
'''| [[Rivaroxaban clinical studies|Clinical Studies]]'''
'''| [[Rivaroxaban how supplied storage and handling|How Supplied/Storage and Handling]]'''
'''| [[Rivaroxaban patient counseling information|Patient Counseling Information]]'''
'''| [[Rivaroxaban labels and packages|Labels and Packages]]'''


[[image:riva1.png|800px]]
'''| [[Sildenafil indications and usage|Indications and Usage]]'''
'''| [[Sildenafil dosage and administration|Dosage and Administration]]'''
'''| [[Sildenafil dosage forms and strengths|Dosage Forms and Strengths]]'''
'''| [[Sildenafil contraindications|Contraindications]]'''
'''| [[Sildenafil warnings|Warnings]]'''
'''| [[Sildenafil precautions|Precautioins]]'''
'''| [[Sildenafil adverse reactions|Adverse Reactions]]'''
'''| [[Sildenafil drug interactions|Drug Interactions]]'''
'''| [[Sildenafil use in specific populations|Use in Specific Populations]]'''
'''| [[Sildenafil overdosage|Overdosage]]'''
'''| [[Sildenafil description|Description]]'''
'''| [[Sildenafil clinical pharmacology|Clinical Pharmacology]]'''
'''| [[Sildenafil nonclinical toxicology|Nonclinical Toxicology]]'''
'''| [[Sildenafil clinical studies|Clinical Studies]]'''
'''| [[Sildenafil how supplied storage and handling|How Supplied/Storage and Handling]]'''
'''| [[Sildenafil patient counseling information|Patient Counseling Information]]'''
'''| [[Sildenafil labels and packages|Labels and Packages]]'''
 
==Mechanism of Action==
==Mechanism of Action==
XARELTO is a selective inhibitor of FXa. It does not require a cofactor (such as Anti-thrombin III) for activity. Rivaroxaban inhibits free FXa and prothrombinase activity. Rivaroxaban has no direct effect on platelet aggregation, but indirectly inhibits platelet aggregation induced by thrombin. By inhibiting FXa, rivaroxaban decreases thrombin generation.


==References==
==References==
Line 41: Line 36:
{{Reflist|2}}
{{Reflist|2}}


[[Category:Cardiovascular Drugs]]
[[Category:Drugs]]
[[Category:Drugs]]

Revision as of 15:23, 3 July 2014

Sildenafil
VIAGRA®, REVATIO®, SELDINAFIL® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings
Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Clinical Trials
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Pratik Bahekar, MBBS [2] For patient information, click here.

Overview

Category

US Brand Names

FDA Package Insert

| Indications and Usage | Dosage and Administration | Dosage Forms and Strengths | Contraindications | Warnings | Precautioins | Adverse Reactions | Drug Interactions | Use in Specific Populations | Overdosage | Description | Clinical Pharmacology | Nonclinical Toxicology | Clinical Studies | How Supplied/Storage and Handling | Patient Counseling Information | Labels and Packages

Mechanism of Action

References

Retrieved from "https://www.wikidoc.org/index.php?title=Sandbox/AL&oldid=988108"